



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company

CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2022-23

29th November, 2022

Online Filing at: www.listing.bseindia.com

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE: 524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-I, Block G,
Sandra Kurla Complex, Sandra (E),
Mumbai – 400051
NSE SYMBOL: SYNCOMF

Subject: Submission of disclosure under Regulation 23(9) of SEBI (LODR) Regulation 2015 regarding Disclosure on Related Party Transaction for the half year ended 30th September, 2022.

Dear Sir/Madam,

Pursuant to Regulation 23(9) as amended from time to time, we are pleased to submit the disclosure of Statement of Related Party Transaction for the half year ended on 30th September, 2022. The same is also published on the website of the Company.

You are requested to please take on record our above said information for your reference and record.

Thanking you,
Yours faithfully,
For, SYNCOM FORMULATIONS (INDIA) LIMITED

Prachi
Jain

CS PRACHI JAIN
COMPANY SECRETARY &
COMPLIANCE OFFICER
Encl.:a/a

Digitally signed by Prachi Jain
DN: cn=Prachi Jain,
2.5.4.20=01702070111044844609420,
1.3.6.1.5.5.2.1.1=Prachi Jain,
409123, postalCode=400001,
sn=Prachi Jain,
serialNumber=2401567488407411,
c=IN, email=prachi.jain@syncomf.com,
55848027174, o=Prachi Jain
Date: 2022.11.29 18:59:00 +05'30'



Bringing a smile on every face...

SYNCOM FORMULATIONS (INDIA) LIMITED
Related Party Transactions for the half year ended 30th September, 2022

(Rs. In Lakhs)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

| S. No | Details of the party (listed entity /subsidiary) entering into the transaction | | Details of the counterparty | | | Type of related party transaction (see Note 5) | Value of the related party transaction as approved by the audit committee (see Note 6a) | Value of transaction during the reporting period (see Note 6b) | In case monies are due to either party as a result of the transaction (see Note 1) | | In case any financial indebtedness incurred to make or give loans, inter-corporate deposits, advances or investments | | | Details of the loans, inter-corporate deposits, advances or investments | | | |
|-------|--|--------------|--------------------------------|-------------|---|--|---|--|--|-----------------|--|-------------------|--------|---|-------------------|--------|--------------------|
| | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | | | | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Cost (see Note 7) | Tenure | Nature (loan/ advance/ inter-corporate deposit/ investment) | Interest Rate (%) | Tenure | Secured/ unsecured |
| 1. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Kedarmal Shankarlal Bankda | ADHPB28 52M | Promoters | Management Contracts including for deputation of Employees | 33.00 | 33.00 | NA | NA | | | | | | | |
| 2. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Vijay Shankarlal Bankda | ACYPB23 76G | Promoters | Management Contracts including for deputation of Employees | 24.00 | 24.00 | NA | NA | | | | | | | |
| 3. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Rinki Ankit Bankda | AJIPG801 4B | Promoters Group | Management Contracts including for deputation of Employees | 14.40 | 14.40 | NA | NA | | | | | | | |
| 4. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Kedarmal Shankarlal Bankda | ADHPB28 52M | Promoters | Leases | 10.29 | 10.29 | NA | NA | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|-----|-------------------------------------|--------------|-----------------------------|-------------|--|------------------------------|-------|-------|----|----|--|--|--|--|--|--|--|--|
| 5. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Vijay Shankarlal Bankda | ACYPB23 76G | Promoters | Leases | 1.29 | 1.29 | NA | NA | | | | | | | | |
| 6. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Vimla Bankda | ADHPB28 53L | Promoters Group | Leases | 10.29 | 10.29 | NA | NA | | | | | | | | |
| 7. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Asha Bankda | ADHPB28 54P | Promoters Group | Leases | 2.59 | 2.59 | NA | NA | | | | | | | | |
| 8. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Rahul Bankda | AIQPB22 22B | Promoters Group | Leases | 1.29 | 1.29 | NA | NA | | | | | | | | |
| 9. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Ankit Kedarmal Bankda | AJGPB31 90B | Promoters Group | Short Term Employee Benefits | 12.00 | 12.00 | NA | NA | | | | | | | | |
| 10. | Syncom Formulations (India) Limited | AAFC S6794 R | CS Prachi Jain | BKEPJ787 2G | Key management personnel of entity or parent | Short Term Employee Benefits | 1.69 | 1.69 | NA | NA | | | | | | | | |
| 11. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Vimla Bankda | ADHPB28 53L | Promoters Group | Short Term Employee Benefits | 4.80 | 4.80 | NA | NA | | | | | | | | |
| 12. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Asha Bankda | ADHPB28 54P | Promoters Group | Short Term Employee Benefits | 4.80 | 4.80 | NA | NA | | | | | | | | |
| 13. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Sulabh Bankda | AOCPB23 86Q | Promoters Group | Short Term Employee Benefits | 4.20 | 4.20 | NA | NA | | | | | | | | |

| | | | | | | | | | | | | | | | | | | |
|-----|-------------------------------------|--------------|--------------------------------|-------------|--|------------------------------|--------|--------|--------|--------|--|--|--|--|--|--|--|--|
| 14. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Payal Bankda | AGTPJ97 71A | Promoters Group | Short Term Employee Benefits | 12.00 | 12.00 | NA | NA | | | | | | | | |
| 15. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Rahul Bankda | AIQPB22 22B | Promoters Group | Short Term Employee Benefits | 12.00 | 12.00 | NA | NA | | | | | | | | |
| 16. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Ankur Bankda | AIQPB22 23A | Promoters Group | Short Term Employee Benefits | 12.00 | 12.00 | NA | NA | | | | | | | | |
| 17. | Syncom Formulations (India) Limited | AAFC S6794 R | Synmex Pharma | AEGFS77 68M | Entities with joint control or significant influence over entity | Sale of Goods and Services | 464.96 | 464.96 | 287.23 | 197.54 | | | | | | | | |
| 18. | Syncom Formulations (India) Limited | AAFC S6794 R | Vincit International | AATFV37 42P | Entities with joint control or significant influence over entity | Sale of Goods and Services | 579.46 | 579.46 | 333.18 | -35.89 | | | | | | | | |
| 19. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Kedarmal Shankarlal Bankda | ADHPB28 52M | Promoter | Equity Investment | 451.20 | 451.20 | NA | NA | | | | | | | | |
| 20. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Vimla Bankda | ADHPB28 53L | Promoters Group | Equity Investment | 752.88 | 752.88 | NA | NA | | | | | | | | |
| 21. | Syncom Formulations (India) Limited | AAFC S6794 R | Mrs. Asha Bankda | ADHPB28 54P | Promoters Group | Equity Investment | 135.00 | 135.00 | NA | NA | | | | | | | | |
| 22. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Ankit Kedarmal Bankda | AJGPB31 90B | Promoters Group | Unsecured Receivables | 0.00 | 0.00 | 0.15 | 0.00 | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | |
|---------------------------|-------------------------------------|--------------|--|-------------|--|-------------------------------------|------|---------|---------|--------|--------|--|--|--|--|--|--|--|--|
| 23. | Syncom Formulations (India) Limited | AAFC S6794 R | Mr. Rahul Bankda | AIQPB22 22B | Promoters Group | Unsecured Receivables | 0.00 | 0.00 | 3.83 | 0.00 | | | | | | | | | |
| 24. | Syncom Formulations (India) Limited | AAFC S6794 R | Krishna Das Neema | AASPN68 02D | Other related party | Sitting Fees & Sitting Fees Payable | 0.25 | 0.25 | 0.00 | 0.05 | | | | | | | | | |
| 25. | Syncom Formulations (India) Limited | AAFC S6794 R | Vinod Kumar Kabra | ACSPK97 86B | Other related party | Sitting Fees & Sitting Fees Payable | 0.20 | 0.20 | 0.00 | 0.05 | | | | | | | | | |
| 26. | Syncom Formulations (India) Limited | AAFC S6794 R | Praveen Jindal | AEAPJ43 67B | Other related party | Sitting Fees & Sitting Fees Payable | 0.15 | 0.15 | 0.00 | 0.05 | | | | | | | | | |
| 27. | Syncom Formulations (India) Limited | AAFC S6794 R | Ruchi Jindal | BLQPB13 52Q | Other related party | Sitting Fees & Sitting Fees Payable | 0.05 | 0.05 | 0.00 | 0.00 | | | | | | | | | |
| 28. | Syncom Formulations (India) Limited | AAFC S6794 R | Synmex Pharma Private Limited | ABJCS02 53J | Entities with joint control or significant influence over entity | Equity Investment | 1.00 | 1.00 | 0.00 | 1.00 | | | | | | | | | |
| 29. | Syncom Formulations (India) Limited | AAFC S6794 R | Vincit Biotech International Private Limited | AAICV89 17E | Entities with joint control or significant influence over entity | Equity Investment | 1.00 | 1.00 | 0.00 | 1.00 | | | | | | | | | |
| 30.. | Syncom Formulations (India) Limited | AAFC S6794 R | Sante Biotech Private Limited | ABJCS02 48M | Entities with joint control or significant influence over entity | Equity Investment | 1.00 | 1.00 | 0.00 | 1.00 | | | | | | | | | |
| Total (of Note 6b) | | | | | | | | 2547.79 | 2547.79 | 624.39 | 164.80 | | | | | | | | |

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.

3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
6. In case of a multi-year related party transaction:
 - a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
 - b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
7. Cost" refers to the cost of borrowed funds for the listed entity.
8. PAN will not be displayed on the website of the Stock Exchange(s).
9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.

FOR, SYNCOM FORMULATIONS (INDIA) LIMITED

**KEDARMAL
SHANKARLAL BANKDA**

Digitally signed by KEDARMAL SHANKARLAL BANKDA
DN: cn=IN, postalCode=452018, st=MADHYA PRADESH, l=INDORE,
o=Personal,
serialNumber=aa678d9f25a59da339a76acc6a5ba06d3933597b3c8e4ab
60128d2208c26ad, pseudonym=003120211209131905209,
2.5.4.20=cbf68d3b709b231b7cddcb4a453fb3d3c675604f0f5ccfaa115815
0eea348fc, email=KEDARBANKDA@GMAIL.COM, cn=KEDARMAL
SHANKARLAL BANKDA, title=0031
Date: 2022.11.29 18:20:13 +05'30'

**KEDARMAL SHANKARLAL BANKDA
CHAIRMAN & WHOLE-TIME DIRECTOR
DIN: 00023050**